The More Life Company Reports Positive Third-Party Agrarius Potato Trial Results in Brazil

Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs

TORONTO--(BUSINESS WIRE)--The More Life Company Corp. (the “Company” or “TMLC”) (CSE: MLCO) (OTCID: TMLCF) is pleased to report positive results from an independently conducted field trial evaluating the Company’s licensed Agrarius™ agricultural plant signaling technology in potato crops in Brazil.

The leading Agrarius application programs recorded numerical yield increases of up to 32.5% in special-grade potatoes and up to 27.6% in total potato yield compared with the control.

The study was independently designed and conducted by G12 Agro Serviços Agropecuários Ltda. (“G12 Agro”), a Brazilian agricultural research and consulting organization, in the municipality of Itaí, in São Paulo, Brazil.

The trial evaluated Agrarius on the Orquestra table-potato cultivar using a randomized complete block design consisting of six treatments and four replications. The study assessed stand count, total yield and tuber classification, including special-grade potatoes measuring between 45 and 70 millimetres.

POSITIVE YIELD RESULTS FROM POST-EMERGENCE APPLICATIONS

The trial evaluated Agrarius under several application-timing programs. The strongest numerical outcomes were observed in the programs involving applications after crop emergence:

• Single Application at 25 Days After Emergence: The Agrarius program produced 30.4 tonnes per hectare of special-grade potatoes compared with 24.6 tonnes per hectare for the control. This represented an increase of 5.8 tonnes per hectare, or approximately 23.6%. The same program produced the highest total yield in the trial at 41.1 tonnes per hectare compared with 32.2 tonnes per hectare for the control, an increase of 8.9 tonnes per hectare, or approximately 27.6%.
• Applications at 25 and 45 Days After Emergence: The Agrarius program produced the highest special-grade yield in the trial at 32.6 tonnes per hectare compared with 24.6 tonnes per hectare for the control. This represented an increase of 8.0 tonnes per hectare, or approximately 32.5%. Total yield was 40.4 tonnes per hectare compared with 32.2 tonnes per hectare for the control, an increase of 8.2 tonnes per hectare, or approximately 25.5%.

The results identified post-emergence application as the most promising timing evaluated in the trial. The single application at 25 days after emergence generated the highest total yield, while the two-application program at 25 and 45 days after emergence generated the highest yield of special-grade potatoes.

Importantly, the commercial benefit observed in the trial extended beyond total crop production. Both leading post-emergence Agrarius programs produced a greater absolute yield of special-grade potatoes, the higher-value 45 to 70 millimetre commercial category. In the two-application program, special-grade potatoes represented approximately 80.7% of total yield, compared with approximately 76.4% in the control, demonstrating a greater concentration of the harvested crop within the higher-value classification. The Company’s LATAM team also observed thicker, more resistant skin in the Agrarius-treated potatoes at harvest, an attribute that may support improved handling durability and longer shelf life. Skin characteristics and shelf life were not formal assessment endpoints in this trial and will require further evaluation.

“We see this as a very encouraging result because it combines independent execution, a randomized field design and a commercial crop outcome that growers would be expected to immediately understand: more tonnes per hectare, particularly in the important 45 to 70 millimetre category,” said Dennis Hancock, President and CEO of The More Life Company. “The highest-performing Agrarius programs produced between 5.8 and 8.0 additional tonnes per hectare of special-grade potatoes and as much as 8.9 additional tonnes per hectare in total yield compared with the control. We feel that this is the kind of practical field evidence that can strengthen customer discussions, help refine application protocols and support our objective for broader commercial adoption. This potato trial is also one of several Agrarius results we expect to report over the coming months as we seek to continue building a credible body of crop-specific, third-party field evidence.”

POTENTIAL GROWER ECONOMICS

The 8.0 tonnes per hectare increase in special-grade potatoes recorded by the highest-performing Agrarius application program is equivalent to approximately 320 additional 25-kilogram bags per hectare. Using an illustrative price of R$70 per bag, the observed numerical yield increase could represent approximately R$22,400 in incremental gross crop value per hectare, equivalent to approximately US$4,400 per hectare based on a reference exchange rate of R$5.09 per US$1.

Brazilian potato prices vary materially by season. This estimate is illustrative, is based on the observed numerical yield difference in this individual trial and does not represent profit or a guaranteed economic return. Actual value realized by a grower would depend on potato grade, prevailing market prices, production costs, application costs, harvesting, transportation and other operating factors.

“When we translate this result into potential value at the farm level, its potential commercial relevance becomes clear,” said Spiros Fournogerakis, Vice President of LATAM Operations for The More Life Company. “The additional 8.0 tonnes of special-grade potatoes is equivalent to approximately 320 additional 25-kilogram bags per hectare. While potato pricing varies considerably by season, the scale of the potential farm-level value would be expected to be a commercially relevant outcome for growers and distribution partners across the region.”

BUILDING A BROADER BODY OF AGRARIUS FIELD EVIDENCE

The new results build upon a separate independent potato field evaluation reported by the Company in 2025, in which the Agrarius-treated area produced 51.25 tonnes per hectare compared with 43.25 tonnes per hectare in the control area, representing an approximately 18.5% productivity increase.

The two evaluations were conducted under different protocols and growing conditions and should not be interpreted as direct replications. The newly completed study provides an additional positive potato data point through an independently managed, randomized field trial and may offer practical direction regarding application timing for future validation and commercial programs.

The Company intends to use the findings to support continued potato validation, application-protocol refinement and commercial discussions with growers, distributors and other agricultural partners.

ABOUT THE MORE LIFE COMPANY CORP.

The More Life Company Corp. is building an organization focused on improving measurable biological performance across its two primary business pillars, Agriculture and Human Health.

The Company’s owned and licensed technology portfolio includes:

• Licensed Agrarius™ agricultural plant signaling technology, designed to improve crop productivity, enhance plant resilience and support more efficient use of agricultural inputs.
• Patented Quicksome™ oral formulation and delivery technologies, designed to support rapid onset, improved bioavailability and precise dosing across nutraceutical and pharmaceutical applications.
• Patented Quicksol™ solubility formulation technology, developed to improve the solubility and delivery of selected active pharmaceutical ingredients.

Through its Agriculture business, the Company is focused on the validation, registration, distribution and commercialization of Agrarius across selected crops and geographic markets. Through its Human Health business, the Company is advancing applications of its proprietary delivery technologies through formulation development, licensing and strategic commercial partnerships.

For more Company information and contact details, visit themorelife.company.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by words such as “anticipate,” “plan,” “estimate,” “expect,” “may,” “will,” “intend,” “should,” and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.

Forward-looking information in this news release includes, but is not limited to, statements concerning additional Agrarius trial results expected to be reported by the Company; the conduct and results of future trials; the repeatability of trial results across other crop seasons, locations and growing conditions; continued validation and refinement of Agrarius application protocols; the estimated economic value of incremental crop yield; the use of trial results in customer and commercial discussions; prospective customer adoption; and the potential commercialization and scaling of Agrarius.

The Company’s actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, agricultural and environmental conditions, commodity prices, currency exchange rates, the ability to reproduce trial results, customer and distributor decisions, competitive factors, prevailing economic conditions and other factors, many of which are beyond the control of the Company.

The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct, and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company’s expectations as of the date hereof. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Neither the CSE nor OTC Markets has reviewed or approved the contents of this news release.